Similar Papers

Paper Title
Journal
Date
Author
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
Enrique Z Fisman ... Alexander Tenenbaum
Cardiovascular Diabetology | VOL. 20
Enrique Z Fisman, et. al.Enrique Z Fisman ... Alexander Tenenbaum
24 Nov 2021
Tirzepatide and the new era of twincretins for diabetes
Tricia M-M Tan ... Bernard Khoo
The Lancet | VOL. 398
Tricia M-M Tan, et. al.Tricia M-M Tan ... Bernard Khoo
27 Jun 2021
META-ANALYSIS OF THE EFFECT OF DUAL GIP AND GLP-1 RECEPTOR AGONISTS ON BLOOD PRESSURE LEVELS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Dimitrios Patoulias ... Maria Toumpourleka
Journal of Hypertension | VOL. 40
Dimitrios Patoulias, et. al.Dimitrios Patoulias ... Maria Toumpourleka
01 Jun 2022
Short-term cost-effectiveness analysis of tirzepatide for the treatment of type 2 diabetes in the United States.
Xiaotong Zhang ... Carrie Mcadam Marx
Journal of Managed Care & Specialty Pharmacy | VOL. 29
Xiaotong Zhang, et. al.Xiaotong Zhang ... Carrie Mcadam Marx
01 Mar 2023
View more papers

More From: The Lancet

Paper Title
Journal
Date
Author
First phase 3 trial of GLP-1 receptor agonist for neurodegeneration
Lorraine V Kalia
The Lancet | VOL. -
Lorraine V KaliaLorraine V Kalia
01 Feb 2025
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial
Nirosen Vijiaratnam ... Tom Foltynie
The Lancet | VOL. -
Nirosen Vijiaratnam, et. al.Nirosen Vijiaratnam ... Tom Foltynie
01 Feb 2025
Preparing for the next pandemic
Devi Sridhar
The Lancet | VOL. 405
Devi SridharDevi Sridhar
01 Feb 2025
The RDI–Lancet Commission on Rare Diseases: improving visibility to address health-care disparities for 400 million people
Kym M Boycott ... Roberto Giugliani
The Lancet | VOL. -
Kym M Boycott, et. al.Kym M Boycott ... Roberto Giugliani
01 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.